Auxilium Pharmaceuticals (AUXL) Gets Pumped Up by Barron's
Tweet Send to a FriendGet Alerts AUXL Hot Sheet
Up)
Trade AUXL Now!
Barron's did a positive piece on Auxilium Pharmaceuticals (Nasdaq: AUXL) this weekend, sending the stock higher today. Shares of Auxilium gapped about 4% to start today's trading session, but have come off those highs since. The stock most recently traded at $38.62, up $1.22, or about $3.3% from last week's close.
Auxilium's top product, Testim, is "a testosterone-based gel designed to help men lead longer, more energetic lives." The ointment currently brings in about $120 million in sales for Auxilium annually, and this number is expected to rise by about 20% a year.
Next, the Barron's article mentions Auxilium's drug, Xiaflex, which is currently in late-stage trials. Some analysts believe the product could hold even more potential for Auxilium than Testim. Xiaflex is targeted for the treatment of a hand disorder called Dupuytren's contracture, a market which could reach $200 million by 2011.
One fund believes shares of Auxilium could hit $100 within the next 3 years: using conservative valuations, the manager estimates the Testim segment could be worth $1 billion, while its Xiaflex business could be valued at about $3 billion.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, orthopedists, and select primary care physicians primarily in the United States.
Auxilium's top product, Testim, is "a testosterone-based gel designed to help men lead longer, more energetic lives." The ointment currently brings in about $120 million in sales for Auxilium annually, and this number is expected to rise by about 20% a year.
Next, the Barron's article mentions Auxilium's drug, Xiaflex, which is currently in late-stage trials. Some analysts believe the product could hold even more potential for Auxilium than Testim. Xiaflex is targeted for the treatment of a hand disorder called Dupuytren's contracture, a market which could reach $200 million by 2011.
One fund believes shares of Auxilium could hit $100 within the next 3 years: using conservative valuations, the manager estimates the Testim segment could be worth $1 billion, while its Xiaflex business could be valued at about $3 billion.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, orthopedists, and select primary care physicians primarily in the United States.
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- Like Microsoft (MSFT) Xbox 360 Games? Don't Buy an Xbox One...
- Cummins (CMI) Could Gain on Strong Int'l Presence, Move to Nat Gas - Barron's
Create E-mail Alert Related Categories
Insiders' BlogRelated Entities
Barron's
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
